CTIC - CTI BioPharma Corp.
| Previous Close | 0.9200 |
| Open | 0.9400 |
| Bid | 0.0000 x 2200 |
| Ask | 0.0000 x 800 |
| Day's Range | 0.9200 - 0.9700 |
| 52 Week Range | 0.6000 - 1.6500 |
| Volume | 15,789 |
| Avg. Volume | 126,117 |
| Market Cap | 53.051M |
| Beta (3Y Monthly) | 1.59 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.5340 |
| Earnings Date | Nov 4, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 4.00 |
- PR Newswire
CTI BioPharma Announces Presentations at the 61st American Society of Hematology Meeting
SEATTLE , Nov. 6, 2019 /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC) today announced four poster presentations and one oral presentation supporting the Company's pacritinib development program at ...
- PR Newswire
CTI BioPharma Reports Third Quarter 2019 Financial Results
SEATTLE , Nov. 4, 2019 /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC) today reported its financial results for the third quarter and nine months ended September 30, 2019 . "We advanced our pacritinib ...
- PR Newswire
CTI BioPharma Begins Patient Enrollment in PACIFICA Pivotal Phase 3 Trial of Pacritinib in Myelofibrosis Patients With Severe Thrombocytopenia
SEATTLE, Oct. 1, 2019 /PRNewswire/ -- CTI BioPharma Corp. (CTIC) today announced that it has initiated patient enrollment in the PACIFICA pivotal Phase 3 trial of its investigational myelofibrosis treatment candidate, pacritinib. The PACIFICA trial will compare the safety and efficacy of 200 mg of pacritinib administered twice daily (BID) to Physician's Choice in 180 adult myelofibrosis patients with severe thrombocytopenia (platelet counts of less than 50,000 per microliter). "Initiation of the PACIFICA Phase 3 trial is an important step forward for the company and the pacritinib development program," said Adam R. Craig, M.D., Ph.D., President and Chief Executive Officer of CTI BioPharma.
- PR Newswire
CTI BioPharma Reports Second Quarter 2019 Financial Results
SEATTLE , Aug. 1, 2019 /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC) today reported its financial results for the second quarter and six months ended June 30, 2019 . "We remain focused on advancing ...
- PR Newswire
CTI BioPharma Announces Outcome From End-of-Phase-2a Meeting With U.S. Food and Drug Administration (FDA) Regarding Pacritinib for Treatment of Myelofibrosis
SEATTLE, July 18, 2019 /PRNewswire/ -- CTI BioPharma Corp. (CTIC) ("CTI" or "the Company") today announced the outcome of a Type B, End-of-Phase-2a meeting with the U.S. Food and Drug Administration ("FDA" or "the Agency") for the continued development of its investigational myelofibrosis treatment candidate, pacritinib. Following this meeting, CTI plans to evaluate 200 mg of pacritinib administered twice daily (BID) in 180 patients with myelofibrosis and severe thrombocytopenia.
- PR Newswire
CTI BioPharma to Present at the JMP Securities Life Sciences Conference on Thursday, Jun. 20
SEATTLE , June 13, 2019 /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma) (NASDAQ: CTIC) today announced that management will provide a corporate overview at the JMP Securities Life Sciences Conference ...
- PR Newswire
CTI BioPharma to Present at the Jefferies Global Healthcare Conference on Wednesday, Jun. 5
SEATTLE , May 29, 2019 /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma) (NASDAQ: CTIC) today announced that management will provide a corporate overview at the Jefferies Global Healthcare Conference ...
- Associated Press
CTI BioPharma: 1Q Earnings Snapshot
The Seattle-based company said it had a loss of 19 cents per share. The biotechnology company posted revenue of $640,000 in the period. In the final minutes of trading on Thursday, the company's shares ...
- PR Newswire
CTI BioPharma Reports First Quarter 2019 Financial Results
SEATTLE , May 2, 2019 /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC) today reported its financial results for the first quarter ended March 31, 2019 . "Advancing our U.S. and European development ...
- PR Newswire
CTI BioPharma to Present at the 18th Annual Needham Healthcare Conference on Wednesday, Apr. 10
SEATTLE , April 3, 2019 /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma) (NASDAQ: CTIC) today announced that management will provide a corporate overview at the 18 th Annual Needham Healthcare Conference ...
- Associated Press
CTI BioPharma: 4Q Earnings Snapshot
On a per-share basis, the Seattle-based company said it had profit of 1 cent. The biotechnology company posted revenue of $14.1 million in the period. For the year, the company reported that its loss narrowed ...
- PR Newswire
CTI BioPharma Reports Fourth Quarter and Full Year 2018 Financial Results and Recent Highlights
SEATTLE , March 13, 2019 /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC) today reported financial results for the fourth quarter and full year ended December 31, 2018 . "The Company is focused ...
- PR Newswire
CTI BioPharma to Present at Oppenheimer's 29th Annual Healthcare Conference on Tuesday, Mar. 19
SEATTLE , March 12, 2019 /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma) (NASDAQ: CTIC) today announced that management will provide a corporate overview at Oppenheimer's 29 th Annual Healthcare Conference ...
- PR Newswire
CTI BioPharma to Present at the 8th Annual SVB Leerink Global Healthcare Conference Wednesday, Feb. 27
SEATTLE , Feb. 20, 2019 /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma) (NASDAQ: CTIC) today announced that management will provide a corporate overview at the 8th Annual SVB Leerink Global Healthcare ...
- PR Newswire
CTI BioPharma Receives $10 Million Milestone Payment for TRISENOX®
SEATTLE , Feb. 11, 2019 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ:CTIC) today announced that it has received a $10 million milestone payment from Teva Pharmaceutical Industries Ltd. related to the achievement ...
- PR Newswire
CTI BioPharma Receives Results of the CHMP Oral Explanation for Pacritinib in the Treatment of Myelofibrosis and Provides Development Update
SEATTLE, Feb. 1, 2019 /PRNewswire/ -- CTI BioPharma Corp. (CTIC) today announced that the Company will withdraw its European Marketing Authorization Application (MAA) for pacritinib as a treatment for myelofibrosis. The decision follows recent interactions with the European Medicine Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP), during which the Company learned that the committee was likely to formally adopt a negative opinion in its evaluation of the application. The Company is continuing to develop pacritinib for both U.S. and European registration as a treatment for myelofibrosis patients with severe thrombocytopenia. CTI plans to seek scientific guidance from the EMA before beginning the planned Phase 3 study, having already discussed the protocol design with the FDA last month. The Phase 3 trial is expected to begin enrollment in the third quarter of 2019.
- PR Newswire
CTI BioPharma Announces Completion of Enrollment in the Phase 2 PAC203 Study of Pacritinib
The Company expects to report the determination of the optimal dose of pacritinib in mid-2019 following a meeting with the U.S. Food and Drug Administration (FDA). Topline efficacy and safety data are expected in the third quarter of 2019, with the new Phase 3 study targeted to commence enrollment in the third quarter of 2019.
- PR Newswire
CTI BioPharma Provides Program Update Following Regulatory Feedback from the U.S. FDA on Pacritinib Development
SEATTLE, Dec. 18, 2018 /PRNewswire/ -- CTI BioPharma Corp. (CTIC) announced today that it has received input from the U.S. Food and Drug Administration (FDA) at a recent Type C meeting on key elements of the design of a new randomized Phase 3 study of pacritinib in adult patients with myelofibrosis (primary myelofibrosis, post-polycythemia vera myelofibrosis, or post-essential thrombocythemia myelofibrosis) and who have severe thrombocytopenia (as defined by patients with platelet counts of less than 50,000 per microliter), an indication that has been recognized by the medical community as an important unmet medical need.
- Benzinga
The Daily Biotech Pulse: Axovant In-Licenses 2 Gene Therapies, Agile To Undertake Additional Study Of Contraceptive Patch
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak (Biotech stocks hitting 52-week highs on Dec. 13) Kezar Life Sciences Inc (NASDAQ: KZR ) Down In The Dumps ...
- PR Newswire
CTI BioPharma Announces Restructuring Plan
SEATTLE, Dec. 13, 2018 /PRNewswire/ -- CTI BioPharma Corp. (CTIC) announced today a restructuring plan to improve efficiencies and reduce costs within the organization. As part of this plan, workforce reductions have been implemented that impact approximately 50 percent of the total number of the Company's employees. Cost savings of approximately $20 million primarily associated with reduced employee costs are expected over three years.